Novartis (NVS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, HSR Act, in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share, of Tourmaline Bio (TRML), a Delaware corporation, at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding. The expiration of the HSR Act waiting period occurred at 11:59 p.m., Eastern Time, on October 21, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis announces Cosentyx met primary endpoint in Phase III REPLENISH trial
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Novartis presents new Pluvicto data, showed improvement in rPFS
- Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
- Novartis announces results from five-year analysis of NATALEE trial of Kisqali